From Splicing Fundamentals to Spinraza: How Decades of Research Paved the Way
How one drug proved RNA can be programmed — and why we can now do it faster, cheaper, and more systematically.
Spinraza Showed What's Possible
Imagine a disease that slowly steals a child's ability to move, swallow, and breathe. That's spinal muscular atrophy (SMA). For decades, families had supportive care — but no real fix.
Then something revolutionary happened: scientists realized SMA wasn't only a “DNA problem.” It was also an RNA problem. The body has two very similar genes: SMN1 (broken in SMA) and SMN2 (almost a backup). SMN2 could help — but it usually makes the wrong RNA message because it skips a crucial piece (exon 7). That means it produces too little functional SMN protein.
The breakthrough idea: don't replace the gene — fix the message.
That's what Spinraza (nusinersen) does. It's a short, specially engineered molecule — an antisense oligonucleotide (ASO) — that binds the SMN2 RNA and forces the cell to include that missing piece. In clinical trials, this changed outcomes dramatically — children who would never sit up began reaching milestones. A once-devastating diagnosis became treatable.
Spinraza proved a bigger point: RNA can be programmed.
Spinraza proved that RNA can be programmed — and the discovery path was powered by extraordinary biology insight and rigorous iterative screening. That foundational work created the knowledge base we build on today. Now, with enough molecular understanding and multi-omics data, we can complement experimental screening with rational, evidence-driven design.
ASOlutions exists because academic RNA scientists lived that bottleneck firsthand. We are researchers trained in splicing and RNA regulation — driven not only to discover new treatments, but to push the field of RNA biology forward by making mechanistic target selection faster, more rigorous, and more reproducible.
Groundbreaking Science Built the Foundation
The discovery of nusinersen was a triumph of deep biological insight and rigorous experimental work. Scientists systematically screened candidate molecules and learned — through careful experimentation — which regions mattered most.
That pioneering effort created the knowledge base that makes computational design possible today.
The ASO Walk: How Nusinersen Was Found
An “ASO walk” is a systematic screening method where many ASOs are designed to tile across a target region of the RNA. By testing dozens or even hundreds of overlapping ASOs, researchers identify “hotspots” — sites where ASO binding causes a desirable splicing change.
Exon 7 Walk (2006–2007): Yimin Hua in Krainer's lab surveyed ASOs targeting various parts of exon 7. They found a few ASOs that increased exon 7 inclusion — hinting at which RNA segments were important.
Intron 7 Walk (2007–2008): The team screened ASOs across the intronic regions and zeroed in on ISS-N1 — a potent intronic splicing silencer. From 31 ASOs tested, one 18-mer emerged as the winner: ASO 10-27 — which became nusinersen.
Hundreds of candidates tested. Years of iteration. The process worked — but it was laborious and expensive.
Why Now Is a New Era
Today we live in the age of molecular “Google Maps.” We have enormous public and private datasets showing:
The key point: we now have enough orthogonal evidence to treat ASO target selection as an inference problem, not a fishing expedition.
Building on decades of foundational research, we can now complement experimental screening with data-driven design.
Our team takes advantage of the modern era of RNA evidence: isoform atlases, splicing motif knowledge, protein–RNA interaction maps, and an expanding track record of ASO successes and failures. But our purpose goes beyond therapeutics. We help researchers and teams build a smarter experimental plan before touching a pipette — prioritizing the most plausible control points and producing an explainable rationale for why a given region should work.
What We Do (In Plain Terms)
We are an RNA-first design consultancy built by academic splicing experts who turn molecular evidence into rational intervention strategies. We accelerate both discovery science and therapeutic translation by producing explainable targets, candidate ASOs, and validation plans before wet lab time and budget are spent.
The big differentiator: we don't just “generate oligos.” We are a decision-making partner. We help you choose what biological lever to pull, where the regulatory control points likely are, what evidence supports that choice, and what experiments best validate the mechanism. That's valuable even when the goal is a Nature paper, not a drug.
Instead of guessing where to target, we:
Scans a gene's RNA like a landscape
Identifies the best "control points" — regions that influence splicing or expression
Designs candidate antisense sequences
Predicts risk (off-targets, poor accessibility, liabilities)
Outputs a ranked, explainable shortlist for rapid experimental validation
Think of it as taking the “ASO walk” that helped discover Spinraza — and putting expert RNA biologists in your corner to do it smarter and faster.
Instead of synthesizing hundreds of oligos, we enumerate candidate binding windows in silico across exons, introns, and UTRs. Instead of relying on brute-force wet-lab selection, we score windows using mechanistic evidence and data-driven priors. Instead of producing “a sequence,” we deliver a ranked, justified panel — where each candidate is linked to the molecular rationale and the underlying evidence layers.
Why Investors and Clients Should Care
The bottleneck in RNA therapeutics isn't the idea — it's the discovery pipeline. Biotech teams spend enormous time and money moving from “this gene looks interesting” to “we have a candidate molecule we believe in.”
ASOlutions is built to shorten that gap by:
Reducing the number of molecules you need to synthesize and test
Providing mechanistic rationale (not just sequences)
Standardizing the workflow across targets and diseases
Enabling faster iteration and better decision-making earlier
Providing a repeatable methodology rather than a one-off project
That's why ASOlutions is designed to serve more than pharma. Academia and biotech face the same fundamental problem: limited time and money, and too many possible experiments. Our experts turn “Where do we start?” into a ranked, mechanistically justified shortlist of targets and experiments. We can validate, de-risk, or jumpstart projects — by strengthening the strategy upstream of wet lab work.
What ASOlutions Offers
ASOlutions delivers expert RNA biology consulting across three key markets:
Academic Acceleration
Stronger hypotheses, faster iteration, cleaner mechanistic stories, more publishable projects.
- • Target landscape + isoform map
- • Regulatory feature hypothesis
- • Ranked intervention sites
- • Proposed validation experiments
Biotech Discovery Sprint
Fewer cycles of synthesis/testing, better early prioritization, reduced risk, faster milestones.
- • Candidate ASO panel
- • Off-target & liability screening
- • Chemistry + delivery suggestions
- • Lead selection criteria
Therapeutic Program Enablement
Scalable target-to-lead workflows, standardized cross-program design logic.
- • Continuous iterations + feedback loop
- • IP strategy hooks (rationale, novelty)
- • Scale across disease targets
- • Patient advocacy partnerships
Spinraza was the moment RNA therapeutics became undeniable. ASOlutions is the next step: converting the decades of RNA biology that enabled Spinraza into a repeatable, expert-driven design service that any serious team can access. Built by academic RNA experts, we help scientists publish clearer mechanisms and help biotech move faster with less waste — so more ideas become experiments, and more experiments become treatments.
Deep Dive: The Full Scientific Story
For those who want the detailed molecular biology, clinical development, and expert design rationale.
The Founder's Story
From a question that got laughed at to founding ASOlutions
A question that got laughed at
I grew up in Rome — Italian and half Argentinian — in an international school where I loved biology because it felt like a language for patterns. In ninth grade, in 2010, we were studying ecosystems. I raised my hand and asked a question that felt obvious to me: could the human gut be considered an ecosystem, given how many different organisms live there together, competing and cooperating?
The teacher pointed me out. The class laughed. It was the kind of moment that teaches you to keep your curiosity quieter.
But science has a way of vindicating the questions that arrive early. In August 2012, The Economist put the microbiome on its cover and described humans as ecosystems — full of microbial species collaborating and competing, shaping our health as a community rather than a single organism.
That was my first proof that the way my mind connects ideas — across categories, across disciplines — wasn't “stupid.” It was simply ahead of the moment.
That was the first time I saw “parallel thinking” turn into public truth — and it's still how I build: connect mechanisms, systems, and evidence before the field catches up.
The Economist (Aug 18, 2012) — microbiome cover package (“Microbes maketh man”; “Me, myself, us”), popularly framing humans as ecosystems of microbial species.
Scotland to Argentina: finding RNA as my home
I studied molecular biology at the University of Dundee in Scotland. By my third year, I wasn't looking for a “work experience line” on my CV — I was hungry for real science.
That's when I heard about Alberto Kornblihtt in Argentina: one of the major RNA scientists in the world, and a rare kind of leader — someone who not only advances science but defends public education and scientific institutions when they're under threat.
I reached out. He offered an interview in London while he was traveling. I took an eight-hour train from Dundee, showed up for the meeting in a half-wrinkled shirt I'd over-ironed with a steamer, and somehow earned the opportunity to join his lab for an internship in Argentina.
From my first day there, I worked on antisense oligonucleotides (ASOs) and alternative splicing. I wasn't “introduced” to RNA later — RNA therapeutics shaped my scientific identity from the beginning.
The reason we worked on SMA: science that answers a call
There are projects you choose, and projects that choose you.
Alberto Kornblihtt is the reason I learned what it means to do science with integrity. He's internationally recognized for decades of contributions to RNA biology and alternative splicing — a Howard Hughes Medical Institute International Scholar for 15 years, and recipient of the 2025 Bunge & Born Prize in Biochemistry and Molecular Biology. In his world, science isn't a brand — it's a responsibility.
That's why the lab's turn toward spinal muscular atrophy (SMA) wasn't driven by trends. It was driven by people.
In the years before Spinraza was available in Argentina, patient families — through Familias AME Argentina (FAME) — were fighting for their children in a landscape where meaningful treatment access was not guaranteed. It's important to remember the timeline: Spinraza was approved by the FDA in December 2016, but in Argentina nusinersen was only authorized later (ANMAT, March 2019), and national documents from 2020 still described it as the only approved option in the country at that time.
So when families came asking for help, it wasn't abstract. It was urgent.
Alberto was cautious at first. He didn't want to promise what he couldn't deliver — because he respects what families carry. But then something deeper took over: the reflex of a scientist who has spent a lifetime decoding splicing regulation. He believed that if we truly understood how antisense therapy was working inside the cell, we might find leverage to make it better.
And that decision — motivated by ethics as much as intellect — set the stage for what became our work: over years of research with Luciano Marasco and colleagues, and in close collaboration with Adrian Krainer, we discovered that splicing-correcting ASOs can reshape chromatin and transcriptional dynamics around the gene, not just the RNA transcript itself. That insight helped open a path toward improving ASO efficacy by thinking beyond sequence alone and into the molecular landscape the ASO enters.
Cell paper (Cover of the Issue):
“Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy” — Marasco et al., 2022
doi.org/10.1016/j.cell.2022.04.031 →
For me, that work delivered a lasting lesson:
RNA therapeutics is not just about sequence matching. It's about molecular landscapes. Splicing, RNA-binding proteins, transcription dynamics, chromatin state, gene architecture — these are not separate stories. They're one system.
This is the legacy I wanted to honor: a lab that treats basic science as the engine of real-world impact, and a mentor who never forgot that public science exists to serve society.
Science with people in the room
During this period, we worked closely with patient families and advocates — including through Familias AME Argentina (FAME) and advocates like Vanina Sánchez, whose leadership I deeply respect. We presented our work in local and international settings where the audience included scientists, clinicians, and families living with SMA.
That matters, because it changes what “good science” feels like: it's not only rigorous — it's responsible. When you present results to a room that includes a parent whose child depends on the therapy you're studying, you carry that weight differently.
I also presented at major RNA meetings, including Cold Spring Harbor's eukaryotic mRNA processing meeting — where you feel the frontier moving in real time. It's also where I met Adrian Krainer in person — someone whose foundational work in splicing biology helped make Spinraza possible.
Timeline anchors: Spinraza (nusinersen) was FDA-approved Dec 23, 2016. In Argentina, ANMAT authorized nusinersen in March 2019. Argentina's Boletín Oficial (2020) referred to Spinraza as the only approved product for AME in the country at that time.
Academia-grade mechanism. Industry-grade delivery.
During my PhD, I also gained early exposure to industry execution from inside academia. Through a government-accredited high-level technical services program, our lab was contracted by Argentine pharmaceutical companies to run RNA biology assays, validation workflows, and structured reporting.
It taught me how to translate rigorous mechanistic work into deliverables: clear experimental plans, reproducible pipelines, and decision-ready results.
These were standard service collaborations — not endorsements — and I don't reference any confidential details. But they shaped something important in me: I've always been task-oriented and product-minded, even while doing fundamental science.
That experience is a direct ancestor of how ASOlutions operates today: evidence-first design, validation-minded planning, and reports that teams can act on.
Industry taught me scale. RNA taught me meaning.
After my PhD, I went into industry — working in biotechnology across molecular biology and genome engineering. It taught me scale, constraints, and how decisions actually get made when time and money are real.
But my heart stayed in RNA therapeutics — and I couldn't ignore a recurring pattern:
Teams waste enormous time and budget moving from “this gene is interesting” to “we have a rational intervention strategy and a shortlist of candidates we believe in.”
This is the upstream bottleneck. And it exists in academia, biotech, and pharma.
Why I founded ASOlutions
Spinraza was discovered through extraordinary insight, plus years of iterative screening and validation. That effort built the foundation for a new era.
But today we have something the early Spinraza era didn't: massive transcriptomic datasets, isoform atlases, regulatory knowledge, and a growing body of real-world ASO outcomes. We can now treat ASO design less like a search — and more like a structured inference problem.
ASOlutions is the consultancy I wished existed when I was a researcher.
Expert-driven, rational ASO design that helps you choose where to intervene on RNA before you spend months at the bench.
And crucially: it's not only for pharma.
In academia, we help build stronger mechanistic hypotheses and cleaner validation strategies. We can help jumpstart projects, refine experimental plans, and produce more publishable, better-supported models.
In biotech, we reduce expensive cycles — helping teams prioritize candidates, anticipate liabilities earlier, and move faster toward milestones.
In pharma, we provide scalable expertise: a standardized methodology to translate molecular landscape evidence into candidate designs.
That's the heart of the ASOlutions story:
An homage to the legacy that made Spinraza possible
A continuation of RNA biology as a field
A next-gen transformation: putting expert RNA biologists in your corner so more ideas become experiments — and more experiments become treatments
And I'm still actively pushing the science: my first-author paper, currently under review at Molecular Cell, shows that splicing-correcting ASOs reshape 3D chromatin architecture through gene looping — revealing that these therapies remodel far more than we originally assumed.
Read the preprint →Scientific Advisors
Anchoring ASOlutions in publication-grade splicing biology and modern scientific rigor
Prof. Alberto Kornblihtt
Universidad de Buenos Aires (UBA) / CONICET
Prof. Kornblihtt serves as a Scientific Advisor to ASOlutions, providing guidance on scientific strategy, mechanistic validation standards, and translational prioritization for our design methodology.
Scientific strategy and prioritization for our design methodology
Mechanistic validation standards (splicing biology, experimental logic)
Translational framing and scientific quality control
Internationally recognized for decades of contributions to RNA biology and alternative splicing.
Dr. Martín García Sola
Bioinformatician
Dr. García Sola serves as a Scientific Advisor to ASOlutions, providing guidance on bioinformatics methodology, data and annotation integration strategy, computational validation standards, and analytical robustness.
Data ingestion and provenance strategy (RefSeq/Ensembl, isoforms, variants)
Off-target and similarity search methodology standards
Scoring and ranking framework design + reproducibility checks
Benchmarking approach (controls, baselines, evaluation metrics)
Auditability outputs for client reports (why this target, why this candidate)
Participates in a personal capacity.
Dr. Juan Cristóbal Muñoz
Postdoc, University of Cambridge
Dr. Muñoz serves as a Scientific Advisor to ASOlutions, providing guidance on antisense oligonucleotide therapeutics, translational research strategy, and experimental validation design.
ASO mechanism of action and therapeutic design strategy
Translational research planning and experimental validation
Target selection and candidate prioritization from a wet-lab perspective
Participates in a personal capacity.
Scientific Advisor roles; not directors or officers of ASOlutions. Affiliations are listed for identification purposes only.
Ready to Design Your Next ASO?
Whether you're targeting a rare disease, exploring a new gene, or optimizing an existing program — we can help you get from target to candidate faster.